Literature DB >> 27481650

Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria.

Hiroki Nishikawa1, Makoto Shiraki2, Akira Hiramatsu3, Kyoji Moriya4, Keisuke Hino5, Shuhei Nishiguchi1.   

Abstract

Sarcopenia is defined by muscle loss and muscle dysfunction. Sarcopenia is classified into primary and secondary types, based on the cause. Primary sarcopenia is mainly aging-related sarcopenia, whereas secondary sarcopenia is the reduced muscle mass and strength that accompanies an underlying disease. Given the essential role of the liver in metabolism, secondary sarcopenia due to nutritional disorders or other factors can frequently occur in liver disease. In 2015, the Japan Society of Hepatology (JSH) decided to establish its own assessment criteria for sarcopenia in liver disease because the number of liver disease patients with sarcopenia is expected to increase and there is cumulative evidence to indicate sarcopenic patients have poor clinical outcomes. A working group to create assessment criteria for sarcopenia has thus been established by the JSH. In this article, we summarize the current knowledge with regard to sarcopenia and present the assessment criteria for sarcopenia in liver disease proposed by the JSH (1st edition). To the best of our knowledge, this is globally the first proposed assessment criteria for sarcopenia specializing in liver disease.
© 2016 The Japan Society of Hepatology.

Entities:  

Keywords:  assessment criteria; liver disease; mechanism; prognosis; sarcopenia

Year:  2016        PMID: 27481650     DOI: 10.1111/hepr.12774

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  154 in total

1.  Arm Skeletal Muscle Mass Is Associated With the Prognosis of Patients With Cirrhosis.

Authors:  Yoshihiro Shimono; Hirayuki Enomoto; Kyohei Kishino; Ei-Ichiro Moriwaki; Hiroki Nishikawa; Takashi Nishimura; Yoshinori Iwata; Hiroko Iijima; Shuhei Nishiguchi
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Association of an Overhydrated State With the Liver Fibrosis and Prognosis of Cirrhotic Patients.

Authors:  Kyohei Kishino; Hirayuki Enomoto; Yoshihiro Shimono; Ei-Ichiro Moriwaki; Hiroki Nishikawa; Takashi Nishimura; Yoshinori Iwata; Hiroko Iijima; Shuhei Nishiguchi
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

3.  Predictors for Grip Strength Loss in Patients With Chronic Liver Diseases.

Authors:  Hiroki Nishikawa; Kazunori Yoh; Hirayuki Enomoto; Naoto Ikeda; Tomoyuki Takashima; Nobuhiro Aizawa; Takashi Nishimura; Shuhei Nishiguchi; Hiroko Iijima
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

4.  Increase in the skeletal muscle mass to body fat mass ratio predicts the decline in transaminase in patients with nonalcoholic fatty liver disease.

Authors:  Naoki Mizuno; Yuya Seko; Seita Kataoka; Keiichiroh Okuda; Mitsuhiro Furuta; Masashi Takemura; Hiroyoshi Taketani; Tasuku Hara; Atsushi Umemura; Taichiro Nishikawa; Kanji Yamaguchi; Michihisa Moriguchi; Yoshito Itoh
Journal:  J Gastroenterol       Date:  2018-06-14       Impact factor: 7.527

5.  Impact of Preoperative Skeletal Muscle Quality Measurement on Long-Term Survival After Curative Gastrectomy for Locally Advanced Gastric Cancer.

Authors:  Yuhei Waki; Tomoyuki Irino; Rie Makuuchi; Akifumi Notsu; Satoshi Kamiya; Yutaka Tanizawa; Etsuro Bando; Taiichi Kawamura; Masanori Terashima
Journal:  World J Surg       Date:  2019-12       Impact factor: 3.352

6.  Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis.

Authors:  Maiko Namba; Akira Hiramatsu; Hiroshi Aikata; Kenichiro Kodama; Shinsuke Uchikawa; Kazuki Ohya; Kei Morio; Hatsue Fujino; Takashi Nakahara; Eisuke Murakami; Masami Yamauchi; Tomokazu Kawaoka; Masataka Tsuge; Michio Imamura; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2019-09-04       Impact factor: 7.527

7.  Application of transcutaneous ultrasonography for the diagnosis of muscle mass loss in patients with liver cirrhosis.

Authors:  Kazufumi Kobayashi; Hitoshi Maruyama; Soichiro Kiyono; Sadahisa Ogasawara; Eiichiro Suzuki; Yoshihiko Ooka; Tetsuhiro Chiba; Naoya Kato; Tadashi Yamaguchi
Journal:  J Gastroenterol       Date:  2017-08-18       Impact factor: 7.527

8.  Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab.

Authors:  Nalee Kim; Jeong Il Yu; Hee Chul Park; Gyu Sang Yoo; Changhoon Choi; Jung Yong Hong; Ho Yeong Lim; Jeeyun Lee; Moon Seok Choi; Jung Eun Lee; Kyunga Kim
Journal:  Cancer Immunol Immunother       Date:  2020-11-24       Impact factor: 6.968

9.  Sarcopenia and Frailty in Chronic Liver Damage: Common and Different Points.

Authors:  Hiroki Nishikawa; Kazunori Yoh; Hirayuki Enomoto; Yoshinori Iwata; Yoshiyuki Sakai; Kyohei Kishino; Yoshihiro Shimono; Naoto Ikeda; Tomoyuki Takashima; Nobuhiro Aizawa; Ryo Takata; Kunihiro Hasegawa; Takashi Koriyama; Yukihisa Yuri; Takashi Nishimura; Shuhei Nishiguchi; Hiroko Iijima
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

10.  Calf Circumference as a Useful Predictor of Sarcopenia in Patients With Liver Diseases.

Authors:  Hiroki Nishikawa; Kazunori Yoh; Hirayuki Enomoto; Yoshinori Iwata; Yoshiyuki Sakai; Kyohei Kishino; Yoshihiro Shimono; Naoto Ikeda; Tomoyuki Takashima; Nobuhiro Aizawa; Ryo Takata; Kunihiro Hasegawa; Takashi Koriyama; Yukihisa Yuri; Takashi Nishimura; Shuhei Nishiguchi; Hiroko Iijima
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.